Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan L Curry

Showing results (141-150 of 194) with videos related to

Pageof 20
Sort By:
Journal of Cutaneous Pathology|July 10, 2020
Langerhans cell sarcoma involving skin and showing epidermotropism: A comprehensive reviewShira Ronen, Elizabeth Keiser, Katrina M Collins, et al.
Journal for Immunotherapy of Cancer|February 14, 2018
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patientsMichael T Tetzlaff, Kelly C Nelson, Adi Diab, et al.
Virchows Archiv : an International Journal of Pathology|February 19, 2021
Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?Katrina Collins, Jun Gu, Phyu P Aung, et al.
Journal of Cutaneous Pathology|March 6, 2024
Spitz melanocytic neoplasms with MLPH::ALK fusions: Report of two cases with previously unreported features and literature reviewHaneen T Salah, Richard K Yang, Sinchita Roy-Chowdhuri, et al.
Journal of Cutaneous Pathology|June 5, 2026
Dermatologic Toxicities Associated With Novel Pan-RAS/RAF InhibitorsLin J He, Shaymaa Hegazy, Phyu P Aung, et al.
Blood Advances|January 18, 2025
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with novel FGFR1 fusion treated with pemigatinibCarlos A Torres-Cabala, Julia Arreola Yescas, Yue Zhang, et al.
Journal of Cutaneous Pathology|November 19, 2016
Diverse types of dermatologic toxicities from immune checkpoint blockade therapyJonathan L Curry, Michael T Tetzlaff, Priyadharsini Nagarajan, et al.
American Journal of Clinical Oncology|September 4, 2019
Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell TherapyHamzah Abu-Sbeih, Tenglong Tang, Faisal S Ali, et al.
Leukemia Research|June 12, 2022
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidineKunhwa Kim, Alexandre Bazinet, Sanam Loghavi, et al.
Biomed Research International|December 26, 2013
Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomasVicki H Chu, Michael T Tetzlaff, Carlos A Torres-Cabala, et al.
Pageof 20

Showing results (141-150 of 194) with videos related to

Sort By:
Pageof 20
Journal of Cutaneous Pathology|July 10, 2020
Langerhans cell sarcoma involving skin and showing epidermotropism: A comprehensive reviewShira Ronen, Elizabeth Keiser, Katrina M Collins, et al.
Journal for Immunotherapy of Cancer|February 14, 2018
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patientsMichael T Tetzlaff, Kelly C Nelson, Adi Diab, et al.
Virchows Archiv : an International Journal of Pathology|February 19, 2021
Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?Katrina Collins, Jun Gu, Phyu P Aung, et al.
Journal of Cutaneous Pathology|March 6, 2024
Spitz melanocytic neoplasms with MLPH::ALK fusions: Report of two cases with previously unreported features and literature reviewHaneen T Salah, Richard K Yang, Sinchita Roy-Chowdhuri, et al.
Journal of Cutaneous Pathology|June 5, 2026
Dermatologic Toxicities Associated With Novel Pan-RAS/RAF InhibitorsLin J He, Shaymaa Hegazy, Phyu P Aung, et al.
Blood Advances|January 18, 2025
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with novel FGFR1 fusion treated with pemigatinibCarlos A Torres-Cabala, Julia Arreola Yescas, Yue Zhang, et al.
Journal of Cutaneous Pathology|November 19, 2016
Diverse types of dermatologic toxicities from immune checkpoint blockade therapyJonathan L Curry, Michael T Tetzlaff, Priyadharsini Nagarajan, et al.
American Journal of Clinical Oncology|September 4, 2019
Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell TherapyHamzah Abu-Sbeih, Tenglong Tang, Faisal S Ali, et al.
Leukemia Research|June 12, 2022
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidineKunhwa Kim, Alexandre Bazinet, Sanam Loghavi, et al.
Biomed Research International|December 26, 2013
Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomasVicki H Chu, Michael T Tetzlaff, Carlos A Torres-Cabala, et al.
Pageof 20